Genentech’s obtains priority revenue from the U.S. FDA for its Hemophilia A treating drug, Emicizumab
Date: 2017-08-24   Author: Saipriya Iyer  Category: #news

Genentech’s obtains priority revenue from the U.S. FDA for its Hemophilia A treating drug, Emicizumab

The U.S. FDA (Food and Drug Administration) has accepted the BLA (Biologics License Application) of Genentech for licensing its investigational bispecific monoclonal antibody referred as Emicizumab prophylaxis to be used in treating Hemophilia A. The antibody helps in bringing together factors IXa and X, the proteins that help in activating the natural blood clotting characteristic in the human body. For the record, Hemophilia A is basically an inherited disease with clotting factor VIII causing rise in bleeding, generally among males. The FDA had reviewed the utility of the medicine in treating adults, children, and adolescents with Hemophilia A, and then granted priority review for the drug. Medical research states that one among three persons is affected from Hemophilia A and develops inhibition to standard clotting factor VIII, that obstructs the treatment and creates life-threatening conditions in the individual with excessive bleeding from joints.

Genentech had performed the clinical tests of Emicizumab prophylaxis on children, adolescents, and adults during its Phase III study. Emicizumab was inoculated in the patients through their skin once a week during the trials. Outcomes derived from the experiments conducted on children, adults, and adolescents displayed the medicinal ability of the drug to prevent bleeding and treating hemophilia A. The firm, a prime member of the Roche Group, a key pharmaceutical market giant, has a great reputation of innovating new methods of antibody treatments to fulfill the global medical requirements. It is also collaborating with the U.S. FDA to introduce new prophylactic therapies for finding a hemophilia A cure.

The BLA for Emicizumab prophylaxis is based on Phase III Haven 1 and Haven 2 clinical test outcomes. Genentech had published its experimental data from its Haven 1 experiments in the New England Journal of medicine and declared the outcomes from both its Phase III studies   at the 26th ISTH (International Society on Thrombosis and Haemostasis) Congress held in July 2017.

For the uninitiated, FDA grants priority review designation for the safer drugs having ability to improve the diagnosis and treatment of chronic ailments. The organization had granted a breakthrough therapy designation for Genentech’s antibody for its inoculation in adolescent and adults with hemophilia A in 2015. But the firm is awaiting the decision regarding the approval of the Emicizumab, which is scheduled to be taken on February 23, 2018.  The firm has also submitted data statistics from its Haven 1 and Haven 2 experiments to the European medicine agency for approval. It now remains to be seen if the European Medicines Agency (EMA) will approve of the Emicizumab prophylaxis.



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Facebook claims its EU operations to be at risk due to inquest
Author: Pankaj Singh

Facebook voiced to Ireland’s High Court that it is not sure how it could operate its services in the European Union if the supervisors restrict its data transfer mechanism. The EU regulator of Facebook, the Irish...


ICT Investment Trends in Telco/Service Market 2020 Global Analysis, Trends, Forecast up to 2025
Author: Ashwin Naphade

The ' ICT Investment Trends in Telco/Service market' research added by Market Study Report, LLC, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concernin...


Healthcare Supply Chain Managements Market to Grow at a Stayed CAGR from 2020 to 2025
Author: Ashwin Naphade

The ' Healthcare Supply Chain Managements market' research report added by Market Study Report, LLC, is a thorough analysis of the latest trends prevalent in this business. The report also dispenses valuable statistics about market size, p...